Pharmacokinetics of higenamine in rabbits

被引:1
|
作者
Lo, CF
Chen, CM
机构
[1] TAIPEI MED COLL,SCH PHARM,TAIPEI 110,TAIWAN
[2] TAIPEI MED COLL,GRAD INST PHARMACEUT SCI,TAIPEI 110,TAIWAN
[3] EXECUT YUAN,NATL LABS FOODS & DRUGS,DEPT HLTH,TAIPEI,TAIWAN
[4] NATL RES INST CHINESE MED,TAIPEI,TAIWAN
关键词
higenamine; pharmacokinetics; bioavailability; glucuronidation;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of higenamine were investigated in rabbits by IV bolus, PO route, and IV infusion. Plasma higenamine concentration declined rapidly in a biexponential pattern, with a terminal half-life of 22 min. The AUC increased proportionally with increasing dose, whereas the percentage of unchanged higenamine excreted from urine remained constant when dose was increased. The means of total body clearance, mean residence time, volume of distribution at steady state, and fraction of urinary excretion were 127.7 mL min(-1) kg(-1) 9.28 min, 1.44 L kg(-1), and 54.8%, respectively. The mean percentage of protein binding of higenamine in plasma was 54.8% at steady state after IV infusion. The results from post-infusion also confirmed that higenamine followed a two-compartment open model in animals. After oral administration, higenamine was rapidly absorbed to reach peak. concentration within 10 min. Interestingly, the plasma concentration-time profiles revealed two distinguishable groups with different C-max extent of absorption, and urinary excretion. The average absolute bioavailabilities of higenamine calculated by AUCs and accumulated urinary excretion were 21.86 and 2.84% versus 20.19 and 5.50% for the two groups, respectively. Upon hydrolysis of urine samples with beta-glucuronidase, urinary concentrations of higenamine were greatly enhanced in both groups.
引用
收藏
页码:791 / 803
页数:13
相关论文
共 50 条
  • [1] A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
    Sheng Feng
    Ji Jiang
    Pei Hu
    Jian-yan Zhang
    Tao Liu
    Qian Zhao
    Bi-lu Li
    Acta Pharmacologica Sinica, 2012, 33 : 1353 - 1358
  • [2] A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
    Feng, Sheng
    Jiang, Ji
    Hu, Pei
    Zhang, Jian-yan
    Liu, Tao
    Zhao, Qian
    Li, Bi-lu
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (11) : 1353 - 1358
  • [3] EMODIN PHARMACOKINETICS IN RABBITS
    LIANG, JW
    HSIU, SL
    WU, PP
    CHAO, PDL
    PLANTA MEDICA, 1995, 61 (05) : 406 - 408
  • [4] PHARMACOKINETICS OF CEPHAMANDOL IN RABBITS
    KLIMOVA, VS
    BOBROV, VI
    NAZAROVA, OI
    SKALA, LZ
    YAKOVLEV, VP
    KOLKER, II
    ANTIBIOTIKI, 1982, 27 (12): : 914 - 918
  • [5] PHARMACOKINETICS OF CHLORAMPHENICOL IN RABBITS
    GUILLOT, P
    SANDERS, P
    MOUROT, D
    ANNALES DE RECHERCHES VETERINAIRES, 1988, 19 (01): : 27 - 33
  • [6] PHARMACOKINETICS OF HABUTOBIN IN RABBITS
    NAKAMURA, M
    KINJOH, K
    MIYAGI, C
    OKA, U
    SUNAGAWA, M
    YAMASHITA, S
    KOSUGI, T
    TOXICON, 1995, 33 (09) : 1201 - 1206
  • [7] PHARMACOKINETICS OF AMYGDALIN IN RABBITS
    ZHANG, GM
    JIN, BQ
    ACTA PHARMACOLOGICA SINICA, 1986, 7 (05): : 460 - 462
  • [8] PHARMACOKINETICS OF TRICLABENDAZOLE IN RABBITS
    ALVAREZBUJIDOS, ML
    ORTIZ, AI
    NEGRO, A
    CUBRIA, JC
    ORDONEZ, D
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-PHARMACOLOGY TOXICOLOGY & ENDOCRINOLOGY, 1993, 106 (03): : 805 - 808
  • [9] Pharmacokinetics of deramciclane in rabbits
    Lengyel, J
    Bojti, E
    Bolehovszky, A
    Grézal, G
    Klebovich, I
    Magyar, K
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (11): : 1063 - 1068
  • [10] PHARMACOKINETICS OF CEPHALOSPORINS IN RABBITS
    KLIMOVA, VS
    RUDZIT, EA
    YAKOVLEV, VP
    ANTIBIOTIKI, 1981, 26 (04): : 284 - 287